Benign prostatic hyperplasia evaluation

The therapeutic and adverse effects of dibenyline, finasteride, and a combination of the two in 190 patients with symptomatic benign prostatic hyperplasia have been evaluated (24). Adverse effects were more common with dibenyline than with finasteride alone or in combination with dibenyline. The drop-out rate was higher with dibenyline (16%) than finasteride alone (7.5%) or the two in combination (4.6%). The reported adverse effects are listed in Table 1. 

Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon ), tamsulosin or finasteride. Eur Urol 2005 48 269-76. 

It is not surprising that fatty acids inhibit COX and LOX enzymes due to their structural similarities with arachidonic acid. A supercritical fluid extract from the fruits of Sabal serrulata (also called Serenoa repens Small. Arecaceae) has been utilized for the treatment of benign prostatic hyperplasia (BPH) and non-bacterial prostatitis. The extract was demonstrated as a dual inhibitor of COX and 5-LOX pathways with IC50 at 28.1 pg/ml and 18.0 (ig/ml, respectively. A further evaluation of the supercritical carbon dioxide extract showed the acidic lipophilic fraction, most likely fatty acids, had the same dual inhibitory activities as the parent extract [121]. 

Sanchez-Chapado M, Guil M, Alfaro V, Badiella L, Fernandez-Hernando N. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms snggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. Eur Urol 2000 37(4) 421-7. 

---